Gemfibrozil reduces plasma C-reactive protein levels in abdominally obese men with the atherogenic dyslipidemia of the metabolic syndrome.
Després
Jean-Pierre
JP
Lemieux
Isabelle
I
Pascot
Agnès
A
Alméras
Natalie
N
Dumont
Martine
M
Nadeau
André
A
Bergeron
Jean
J
Prud'homme
Denis
D
D000328:Adult; D001824:Body Constitution; D002097:C-Reactive Protein / Q000032:analysis*; D003324:Coronary Artery Disease / Q000517:prevention & control; D015248:Gemfibrozil / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D000960:Hypolipidemic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D015850:Interleukin-6 / Q000097:blood; D008297:Male; D024821:Metabolic Syndrome / Q000097:blood*; D008875:Middle Aged; D009765:Obesity / Q000097:blood*; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis
D000960:Hypolipidemic Agents; D015850:Interleukin-6; D014409:Tumor Necrosis Factor-alpha; D002097:C-Reactive Protein; D015248:Gemfibrozil